Mold concerns addressed at Amherst-Pelham Regional Middle School
AMHERST, Mass. (WWLP) – An assessment was conducted at Amherst-Pelham Regional Middle School for concerns of mold.
In a news release sent to 22News from the school district, an independent indoor air quality study was requested for portions of the ARMS building, which was previously closed to students and staff. In March, the assessment was conducted by Atlas Technical Consultants. The key findings include the following:
Air Quality: Indoor air samples collected showed mold spore levels that were comparable to outdoor levels. The EMLab MoldScore™ used to evaluate airborne mold presence in various rooms scored between 103–129—well within the 'low' range, suggesting a low likelihood that the detected spores originated indoors.
Surface Sampling: Isolated instances of active mold growth were found on specific surfaces, including wooden shelves, instrument cases, and door frames—particularly in the music and family center areas. Mold types identified included Aspergillus and Cladosporium.
Root Cause: Most mold was attributed to condensation and prolonged humidity, not systemic HVAC failures. Several areas of water damage were also linked to roof drainage issues.
HVAC Systems: Filters in the building's vents had not been replaced since early 2023. ATLAS recommended regular filter replacement and dehumidification, especially during warmer months.
New Amherst Superintendent Dr. Xiomara Herman meets with residents
'We are taking these concerns seriously. Thanks to the diligence of our facilities team, outside experts, and school leaders, we are implementing both short-term fixes and long-term improvements to ensure our learning environment is clean, safe, and healthy for all,' Superintendent Dr. E. Xiomara Herman said in a statement.
To address the issues, the school district has scheduled a professional remediation to take place next week in the music and instrument storage rooms, where mold activity was most significant. Repairs to the roof were made, and a replacement is scheduled for this summer. Air filters in the HVAC have been replaced, and the custodians have cleaned the areas using EPA-recommended mold removal protocols in areas that included the Family Center, library tables, and music storage rooms.
WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on WWLP.com.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Samsung Bioepis Presents Long-Term Safety Data of EPYSQLI™ (Eculizumab) in PNH at the European Hematology Association (EHA) Congress 2025
INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. ('Samsung Bioepis') today presented the long-term safety data of EPYSQLI™ (eculizumab; SB12), a biosimilar to Soliris 1, in paroxysmal nocturnal hemoglobinuria (PNH) at the European Hematology Association (EHA) Congress 2025 held at Milan, Italy from June 12 to 15. Long-term follow-up of EPYSQLI's Phase 3 study showed consistency of safety data between the initial 52-week period and the extended treatment period up to 158 weeks Share EPYSQLI was approved by the European Commission (EC) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) in May 2023 and March 2024, respectively 2. The study assessed the long-term safety of EPYSQLI in PNH patients by evaluating the consistency of safety outcomes, particularly serious adverse events (SAEs) between the initial 52-week Phase 3 study period and the extended treatment (ET) period, spanning from 52 weeks to up to 158 weeks. The same maintenance dose of 900 mg EPYSQLI was administered every 2 weeks. A total of 46 patients from the Phase 3 study received ET. During ET, seven patients (15.2%) experienced a total of 14 SAEs with no occurrence of fatal cases, and all patients fully recovered without permanently discontinuing the treatment. The exposure-adjusted event rate (EAER) was comparable between initial 52-week period and ET period (EAER were 0.13 and 0.17, respectively), and there was no statistically difference between initial 52-week and ET period in EAER (p-value = 0.76). The study is consistent with the findings of the Phase 3 study with no newly identified safety signals and no fatal cases occurred throughout the entire treatment period with all SAEs resolving completely. Details of the abstract are as follows 3: Abstract title: Long-Term Safety of SB12 in Paroxysmal Nocturnal Hemoglobinuria: Up to 2-year Extension Treatment Safety Data Abstract number: PB2811 Type: Publication Only Session title: Bone marrow failure syndromes incl. PNH – Clinical Author(s): Jun Ho Jang, Siook Baek, Yumin Baek, Jinah Jung, Ciprian Tomuleasa, Hanna Oliynyk, Theerin Lanamtieng, Soo Min Lim Besides approval by the EC, EPYSQLI is also approved by the U.S. Food and Drug Administration (FDA) and Korea's Ministry of Food and Drug Safety (MFDS) as a biosimilar to Soliris. In countries where EPYSQLI is approved and available, EPYSQLI may not be prescribed and/or dispensed for its unapproved other indications for which Soliris is approved. About EPYSQLI (Eculizumab Biosimilar) in the European Union (EU) EPYSQLI is indicated in adults and children for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). EPYSQLI is not approved for and should not be used for the treatment of generalised myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). EPYSQLI must be administered by a healthcare professional and under the supervision of a physician experienced in the management of patients with hematological disorders or renal disorders. EPYSQLI EU Important Safety Information The EU Summary of Product Characteristics for EPYSQLI includes the following Special warning and Precautions: Meningococcal Infection Due to its mechanism of action, the use of eculizumab increases the patient's susceptibility to meningococcal infection (Neisseria meningitidis). Meningococcal disease due to any serogroup may occur. To reduce the risk of infection, all patients must be vaccinated at least 2 weeks prior to receiving eculizumab unless the risk of delaying eculizumab therapy outweighs the risks of developing a meningococcal infection. Patients who initiate eculizumab treatment less than 2 weeks after receiving a tetravalent meningococcal vaccine must receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination. Vaccines against serogroups A, C, Y, W 135 are recommended in preventing the commonly pathogenic meningococcal serogroups. Vaccine against serogroup B where available is also recommended. Patients must receive vaccination according to current national vaccination guidelines for vaccination use. Vaccination may further activate complement. As a result, patients with complement-mediated diseases, including PNH and aHUS, may experience increased signs and symptoms of their underlying disease, such as haemolysis (PNH) or TMA (aHUS). Therefore, patients should be closely monitored for disease symptoms after recommended vaccination. Vaccination may not be sufficient to prevent meningococcal infection. Consideration should be given to official guidance on the appropriate use of antibacterial agents. Cases of serious or fatal meningococcal infections have been reported in eculizumab-treated patients. Sepsis is a common presentation of meningococcal infections in patients treated with eculizumab. All patients should be monitored for early signs of meningococcal infection, evaluated immediately if infection is suspected, and treated with appropriate antibiotics if necessary. Patients should be informed of these signs and symptoms and steps taken to seek medical care immediately. Other Systemic Infections Patients may have increased susceptibility to other type of serious infections, especially with Neisseria and encapsulated bacteria. Infusion Reactions Administration of eculizumab may result in infusion reactions or immunogenicity that could cause allergic or hypersensitivity reactions (including anaphylaxis). Eculizumab administration should be interrupted in all patients experiencing severe infusion reactions and appropriate medical therapy administered. Anticoagulant therapy Treatment with eculizumab should not alter anticoagulant management. PNH Laboratory Monitoring PNH patients should be monitored for signs and symptoms of intravascular haemolysis, including serum lactate dehydrogenase (LDH) levels, and may require dose adjustment within the recommended 14±2 day dosing schedule during the maintenance phase (up to every 12 days). aHUS Laboratory Monitoring aHUS patients receiving eculizumab therapy should be monitored for thrombotic microangiopathy by measuring platelet counts, serum LDH and serum creatinine, and may require dose adjustment within the recommended 14±2 day dosing schedule during the maintenance phase (up to every 12 days). Treatment Discontinuation for PNH If patients discontinue treatment with eculizumab they should be closely monitored for signs and symptoms of serious intravascular haemolysis. Treatment Discontinuation for aHUS If aHUS patients discontinue treatment with eculizumab, they should be monitored closely for signs and symptoms of severe thrombotic microangiopathy complications. The most common adverse reaction observed with eculizumab treatment in clinical trials was headache, (occurred mostly in the initial phase of dosing), and the most serious adverse reaction was found to be meningococcal infection. Refer to the Summary of Product Characteristics for EPYSQLI's full safety information.
Yahoo
6 hours ago
- Yahoo
New state health clinic opens in Wyoming County
EATON TOWNSHIP, WYOMING COUNTY (WBRE/WYOU) — A new state health clinic is now officially open in Wyoming County, making health care services more accessible to people who may not have insurance. The Wyoming County State Health Center held its official ribbon-cutting Wednesday afternoon. The move from their old location to Hunter Highway makes it more centrally located and more accessible for patients. The state-run clinic offers free vaccines, STL testing, tuberculosis testing and treatment, and much more for people who qualify. Police looking for suspect in attempted Luzerne County robbery, chase 'The nurses that work here have a vast and incredible experience across all parts of health care, and so they're here to help people,' Department of Health Secretary Dr. Debra Bogen told 28/22 News. 'It's great because you get to know your community partners, so we're able to help people understand where they can go for services and just keep the conversation flowing,' Community Health Nurse Amanda Moyer said. The Wyoming County State Health Center is open weekdays from 8:00 a.m. to 4:00 p.m., and many services are free for those who qualify. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
8 hours ago
- Yahoo
Project Lifesaver launches in Chicopee to help locate wandering individuals
CHICOPEE, Mass. (WWLP) – The Hampden County Sheriff's Department is keeping individuals with cognitive conditions safe in the city of Chicopee with a new program. This program is called 'Project Life-Saver,' and it provides the city's most vulnerable population with a small tracking device to wear, which can be used to locate them if they get lost. Chicopee Fire Department promotes two officers to new ranks Project Life-Saver is a safety system for those with cognitive conditions such as autism or dementia. If they wander off or get lost, which for some could be days or weeks, it helps protect them and bring them back home. 'We always want to hear the word 'rescue' and not the word 'recovery,' and that's just the blunt fact,' said Chicopee Mayor John Vieau. 'And the goal is to rescue people, and that's what we're hopeful this will help us do.' This is a key initiative under the Hampden County TRIAD program, founded in 2021. Members of the Chicopee Police and Fire Departments completed comprehensive training to support the program. The program requires participants to wear a bracelet that can be tracked using radio frequency in case they go missing. Lt. Greg Moss from the Hampden County Sheriff's Department explained how this helps to find them. 'We punch in their specialized radio frequency from the transponder on that, and then we go from where the person is last known, last known location,' Moss said. This helps speed up emergency responders' search and recovery time to under 30 minutes. 'We can pick up their signal no matter where they are,' said Deputy Elizabeth Rodriguez, Triad Officer for the Hampden County Sheriff's Department. 'If they're in the water, if they're in a basement, if they're under a bridge.' Deputy Rodriguez said this not only ensures their safety and well-being, but also brings a peace of mind to their caregivers or loved ones. Each bracelet is free and can work on a person's wrist or ankle. Families interested in enrolling a loved one is asked to call the Hampden County Sheriff's Office at (413) 858-0060. WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
